AIT Therapeutics to Report Second Quarter Financial Results on Friday, August 11
REHOVOT, Israel and NEW YORK, July 27, 2017 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (OTC:AITB), a clinical stage anti-microbial therapeutic company treating respiratory diseases with nitric oxide (NO), will report financial results for the three- and six-months ended June 30, 2017 and host a conference call and webcast at 10:30am Eastern Time on Friday, August 11.
|Conference Call & Webcast|
|Friday, August 11th @ 10:30am Eastern Time|
|Replays available through August 25th:|
About AIT Therapeutics Inc.
AIT Therapeutics Inc. is a clinical-stage anti-microbial therapeutic company developing novel non-antibiotic anti-microbial therapeutics for respiratory diseases based on nitric oxide (NO) as well as other indications. The Company is applying its therapeutic expertise to prevent and treat lower respiratory tract infections, many of which cannot effectively be addressed with current standards of care. AIT Therapeutics is advancing its revolutionary respiratory targeted system in a pipeline of clinical trials for the treatment of bronchiolitis (RSV) exacerbations, and nontuberculous mycobacteria (NTM). For more information, visit www.AIT-Pharm.com.
CONTACT Steven Lisi Chief Executive Officer AIT Therapeutics, Inc. Steve@AIT-Pharm.com Bob Yedid LifeSci Advisors, LLC Bob@LifeSciAdvisors.com (646) 597 6989Source: AIT Therapeutics, Inc.
Released July 27, 2017